Leukemia drug timing under the microscope: new study aims to improve dosing
NCT ID NCT07221656
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how long the drug calaspargase pegol stays at effective levels in the blood of children and young adults with acute lymphoblastic leukemia or lymphoma. Researchers will measure drug activity and check for links to side effects. The goal is to better understand dosing and improve treatment safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diet and exercise program help childhood leukemia survivors live healthier?
- Could bone marrow from deceased donors cure blood cancers?
- Lab-Grown stem cells could speed immune recovery in blood cancer transplants
- New drug cocktail aims to improve remission in older leukemia patients
- Real-World watch on ph+ leukemia treatments aims to uncover best paths to remission
- Radioactive antibody hones in on cancer cells to boost transplant success